Cargando…
Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis
BACKGROUND: Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke. METHODS: We searched PubMed, China National Knowledg...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059049/ https://www.ncbi.nlm.nih.gov/pubmed/27749547 http://dx.doi.org/10.1097/MD.0000000000004904 |
_version_ | 1782459366224429056 |
---|---|
author | Li, Ji-Huang Chen, Zi-Xian Zhang, Xiao-Guang Li, Yan Yang, Wen-Ting Zheng, Xia-Wei Chen, Shuang Lu, Lin Gu, Yong Zheng, Guo-Qing |
author_facet | Li, Ji-Huang Chen, Zi-Xian Zhang, Xiao-Guang Li, Yan Yang, Wen-Ting Zheng, Xia-Wei Chen, Shuang Lu, Lin Gu, Yong Zheng, Guo-Qing |
author_sort | Li, Ji-Huang |
collection | PubMed |
description | BACKGROUND: Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke. METHODS: We searched PubMed, China National Knowledge Infrastructure, WanFang Database, and VIP Database for Chinese Technical Periodicals published from the inception up to November 2015. The primary measured outcome was one of neurogenesis biomarker, including Bromodeoxyuridine (BrdU), Nestin, doublecortin (DCX), polysialylated form of the neural cell adhesion molecule (PSA-NCAM), neuronal nuclear antigen (NeuN), and glial fibrillary acidic protein (GFAP). RESULTS: Thirty eligible studies were identified. The score of quality assessment ranged from 2 of 10 to 7 of 10. Compared with controls, 10 studies conducting neurobehavioral evaluation showed significant effects on bioactive components of CHM for improving neurological deficits score after ischemic insults (P < 0.01 or P < 0.05); 6 studies in Morris water-maze test showed bioactive components of CHM significantly decreased escape latency and increased residence time (P < 0.05); 5 studies demonstrated that bioactive components of CHM significantly reduced infarct volume after ischemic stroke (P < 0.05); 25 of 26 studies showed that bioactive components of CHM significantly increased the expression of BrdU and/or Nestin markers in rats/mice brain after ischemic injury (P < 0.05, or P < 0.01); 4 of 5 studies for promoting the expression of PSA-NCAM or DCX biomarker (P < 0.05); 5 studies for improving the expression of NeuN biomarker (P < 0.05); 6 of 7 studies for promoting the expression of GFAP biomarker in brain after ischemic stroke (P < 0.05). CONCLUSION: The findings suggest that bioactive components of CHM may improve neurological function, reduce infarct volume, and promote endogenous neurogenesis, including proliferation, migration, and differentiation of neural stem cells after ischemic stroke. However, evidences are supported but limited because only a few studies were available for each descriptive analysis. Further rigor study is still needed. |
format | Online Article Text |
id | pubmed-5059049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-50590492016-11-01 Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis Li, Ji-Huang Chen, Zi-Xian Zhang, Xiao-Guang Li, Yan Yang, Wen-Ting Zheng, Xia-Wei Chen, Shuang Lu, Lin Gu, Yong Zheng, Guo-Qing Medicine (Baltimore) 3800 BACKGROUND: Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke. METHODS: We searched PubMed, China National Knowledge Infrastructure, WanFang Database, and VIP Database for Chinese Technical Periodicals published from the inception up to November 2015. The primary measured outcome was one of neurogenesis biomarker, including Bromodeoxyuridine (BrdU), Nestin, doublecortin (DCX), polysialylated form of the neural cell adhesion molecule (PSA-NCAM), neuronal nuclear antigen (NeuN), and glial fibrillary acidic protein (GFAP). RESULTS: Thirty eligible studies were identified. The score of quality assessment ranged from 2 of 10 to 7 of 10. Compared with controls, 10 studies conducting neurobehavioral evaluation showed significant effects on bioactive components of CHM for improving neurological deficits score after ischemic insults (P < 0.01 or P < 0.05); 6 studies in Morris water-maze test showed bioactive components of CHM significantly decreased escape latency and increased residence time (P < 0.05); 5 studies demonstrated that bioactive components of CHM significantly reduced infarct volume after ischemic stroke (P < 0.05); 25 of 26 studies showed that bioactive components of CHM significantly increased the expression of BrdU and/or Nestin markers in rats/mice brain after ischemic injury (P < 0.05, or P < 0.01); 4 of 5 studies for promoting the expression of PSA-NCAM or DCX biomarker (P < 0.05); 5 studies for improving the expression of NeuN biomarker (P < 0.05); 6 of 7 studies for promoting the expression of GFAP biomarker in brain after ischemic stroke (P < 0.05). CONCLUSION: The findings suggest that bioactive components of CHM may improve neurological function, reduce infarct volume, and promote endogenous neurogenesis, including proliferation, migration, and differentiation of neural stem cells after ischemic stroke. However, evidences are supported but limited because only a few studies were available for each descriptive analysis. Further rigor study is still needed. Wolters Kluwer Health 2016-10-07 /pmc/articles/PMC5059049/ /pubmed/27749547 http://dx.doi.org/10.1097/MD.0000000000004904 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 3800 Li, Ji-Huang Chen, Zi-Xian Zhang, Xiao-Guang Li, Yan Yang, Wen-Ting Zheng, Xia-Wei Chen, Shuang Lu, Lin Gu, Yong Zheng, Guo-Qing Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis |
title | Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis |
title_full | Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis |
title_fullStr | Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis |
title_full_unstemmed | Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis |
title_short | Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis |
title_sort | bioactive components of chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: a systematic analysis |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059049/ https://www.ncbi.nlm.nih.gov/pubmed/27749547 http://dx.doi.org/10.1097/MD.0000000000004904 |
work_keys_str_mv | AT lijihuang bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT chenzixian bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT zhangxiaoguang bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT liyan bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT yangwenting bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT zhengxiawei bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT chenshuang bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT lulin bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT guyong bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis AT zhengguoqing bioactivecomponentsofchineseherbalmedicineenhanceendogenousneurogenesisinanimalmodelsofischemicstrokeasystematicanalysis |